[Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients].
The optimal management of prostate cancer patients with lymph node metastasis remains controversial. In this article, the outcome in a consecutive group of patients with newly diagnosed lymph node positive prostate cancer is presented. In 59 patients with histological verified lymph node positive disease but without osseous metastasis, outcome is described by time to biochemical progression, time to metastasis and survival. Median age at diagnosis was 62 years. Median pre-treatment PSA was 21 ng/ml. Endocrine treatment was initiated within median 2 weeks in 97% of the patients. Median follow-up was 3 years. Median time to biochemical progression was 1.8 years and 5-year biochemical recurrence-free survival was 14%. Median time to development of osseous metastasis was 4.4 years and 5-year metastasis-free survival was 49%. Eighteen of the 59 patients died during follow-up, 15 deaths were attributable to prostate cancer. Estimated median survival was 5.5 years. Despite early androgen deprivation therapy, patients with lymph node positive prostate cancer have a grave prognosis with a high risk of progression and disease-specific mortality.